Study on the Safety and Effectiveness of IMC-F106C Alone and with Other Cancer Treatments

Inclusion Criteria

• Must be in good general health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Must have a specific genetic marker called HLA-A*02:01.
• Cancer must be positive for the PRAME marker.
• Cancer must have returned, not responded to, or not tolerated standard treatments, or be used in combination with standard treatments.
• If applicable, must agree to use highly effective birth control methods.

Exclusion Criteria

• Have untreated or symptomatic cancer spread to the brain.
• Have had a recent bowel blockage.
• Have ongoing fluid buildup in the abdomen or chest that needs frequent drainage.
• Have had significant immune-related side effects from previous immunotherapy.
• Have not had enough time since the last cancer treatment to safely start the study drug.
• Have ongoing side effects from previous cancer treatments.
• Have abnormal lab test results.
• Have significant lung, heart, or autoimmune diseases.
• Need ongoing treatment that suppresses the immune system.
• Have had a solid organ or bone marrow transplant.
• Have active infections like hepatitis B, hepatitis C, or HIV.
• Have another significant cancer.
• Have allergies to the study drug or its ingredients.
• Have had antibiotics, vaccines, or surgery within 2-4 weeks before starting the study.
• Are pregnant or breastfeeding.
• Have any other condition that would prevent safe participation in the study.